期刊文献+

人血管性血友病因子裂解蛋白酶pEGFP-N1真核表达载体的构建及其在HeLa细胞中的表达 被引量:1

Construction of ADAMTS13-pEGFP-N1 Vector and Its Expression in HeLa Cells
下载PDF
导出
摘要 本研究旨在构建人血管性血友病因子裂解蛋白酶(ADAMTS13)的pEGFP-N1真核表达载体,为进一步研究ADAMTS13在细胞内合成及其分泌提供有力工具。通过PCR方法获取目的基因片段,并在目的基因两端加上限制性酶切位点。限制性内切酶酶切后,连接至pEGPF-N1真核表达载体。连接后获得质粒进行酶切鉴定及DNA测序验证,并转染HeLa细胞。通过荧光显微镜检测绿色荧光蛋白表达,Western blot方法鉴定所得蛋白。结果表明,酶切鉴定及DNA测序确认目的基因与载体正确连接,在荧光显微镜下观察到绿色荧光。Western blot显示,转染后HeLa细胞表达ADAMTS13蛋白。结论:成功构建了ADAMTS13-pEGFP-N1真核表达载体,为进一步研究ADAMTS13合成、分泌及其代谢的生理学机制提供了研究工具。 This study was aimed to construct a pEGFP-N1 vector of von Willebrand factor cleaving protease (ADAMTS13, a disintegrin and metalloprotease with a thrombospondin type 1 motifs 13) so as to pave the way for further studing its synthesis and secretion. Human full-length cDNA sequence of ADAMTS13 was acquired by polymerase chain reaction(PCR) with Phusion High-Fidelity(NEB) ,then the PCR product was double digested with EcoR I and XhoⅠ.After digestion, the ADAMTS13 cDNA sequence was purified and recombined with the pEGFP-N1 vector. The DNA sequence analysis showed that ADAMTS13 was ligated to the pEGFP-N1 vector correctly. After transient expression in HeLa cells, the expression of EGFP could be detected by fluorescent microscopy, and the expression of ADAMTS13 protein could be detected by SDS-PAGE and Western blot. It is concluded that the ADAMTS13-pEGFP-N1 vector is successfully constructed, and it can be widely used in further research on the mechanism of the synthesis and secretion of ADAMTS13.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2013年第1期126-129,共4页 Journal of Experimental Hematology
基金 江苏高校优势学科建设工程资助项目 江苏省临床医学中心资助(编号ZX201102) 高等学校博士学科点专项科研基金(编号20103201110011)
关键词 ADAMTS13 pEGFP-N1载体 载体构建 HELA细胞 ADAMTS13 pEGFP-N1 vector vector construction HeLa cell
  • 相关文献

参考文献15

  • 1Furlan M, Robles R, Lammle B. Partial purification and charac- terization of a protease from human plasma cleaving yon Willebrand factor to fragments produced by in vivo proteolysis. Blood, 1996; 87(10) : 4223 -4234.
  • 2Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood, 1996;87(10) : 4235 -4244.
  • 3Zheng X, Chung i), Takayama TK, et al. Structure of von Willebrand factor-cleaving protease ( ADAMTS13 ), a metallo- protease involved in thrombotic thrombocytopenic purpura. J Biol Chem, 2001 ;276(44) : 41059 -41063.
  • 4Porter S, Clark IM, Kevorkian L, et al. The ADAMTS metallo- proteinases. Biochem J, 2005; 386(Pt 1 ) : 15 -27.
  • 5Zhou Z, Nguyen TC, Guchhait P, et al. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost, 2010; 36( 1 ) : 71 -81.
  • 6Lotta LA, Garagiola I, Palla R, et al. ADAMTSI3 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat, 2010 ;31(1 ) : I1 - 19.
  • 7Zheng XL, Sadler JE. Pathogenesis of thrombotic micro- angiopathies. Annu Rev Pathol, 2008; 3:249 -277.
  • 8Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA, 2002;99(18) : 11902 -11907.
  • 9Tat Z, Peng Y, Nolasco L, et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood, 2005 ;106(13) : 4139 -4145.
  • 10Gandhi C, Khan MM, Lentz SR, et al. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood, 2012; 119(10): 2385-2391.

同被引文献19

  • 1Tsai HM, Lian EC. Antibodies to von Willebrand fac- tor cleaving protease in acute thrombotic thrombocytope- nic purpura [J]. N Engl Med, 1998, 339: 1585 - 1594.
  • 2Furlan M, Robles R, Solcnthaler M, et al. Deficient activity of yon Willebrand factor - cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura [J]. Blood, 1997, 89: 3097-3103.
  • 3De Maeyer B, De Meyer S F, Feys H B, ct al. The distal carboxyl - terminal domains of murine ADAMTS13 influence proteolysis of platelet - decorated VWF strings in vivo [J]. J Thromb Haemost, 2010, 8 (10): 2305 - 2312.
  • 4Chauhan AK, Motto DG, Lamb CB, et al. Systemic antithrombotic effects of ADAMTS13 [ J ]. J EM, 2006, 203 : 767 -776.
  • 5Yang S, Jin M, Lin S, et al. ADAMTS13 activity and antigen during therapy and follow - up of patients with idiopathic thrombotic thrombocytopenic purpura: corre- lation with clinical outcome [ J ]. Haematologica, 2011, 96 (10): 1521-1527.
  • 6Akiyama M, Nakayama D, Takeda S, et al. Crystal structure and enzymatic activity of an ADAMTS13 mu- tant with the East Asian - specific P475S polymorphism [J]. JTH, 2013, 11 (7): 1399-1406.
  • 7Casonato A, Pontara E, Baniston M, et al. C2362F mutation gives rise to an ADAMTS13 - resistant von Willebrand factor [ J]. Thrombosis and haemostasis, 2013, 109 (5): 999-1006.
  • 8Mannucci PM, Teresa MC, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves yon Willebrand factor [ J ]. Blood, 2001, 98 (9) : 2730 - 2735.
  • 9Enooku K, Kato R, Ikeda H, et al. Inverse correla- tions between serum ADAMTS13 levels and systolic blood pressure, pulse pressure, and serum C - reac- tive protein levels observed at a general health exami- nation in a Japanese population: A cross - sectional study. Clinica chimica acta; international journal of clinical chemistry [J]. Clin Clim Acta, 2013, 421 : 147 - 151.
  • 10Zhao B Q, Chauhan A K, Canauh M, et al. Von Willebrand factor - cleaving protease ADAMTS13 re- duces ischemic brain injury in experimental stroke [J]. Blood, 2009, 114 (15): 3329-3534.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部